Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms

References

• Sugiyama A, Kurisu A, Nagashima S, et al. Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Sci Rep. 2022;12(1):16294. doi:10.1038/s41598-022-20747-x
   PubMed Web of Science ®Google Scholar
• Maeda H, Saito N, Igarashi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;2022:ciac292.
   Google Scholar
• Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune response to SARS-CoV-2 vaccines. Biomedicines. 2022;10(7):1464. doi:10.3390/biomedicines10071464
   PubMed Web of Science ®Google Scholar
• Federico M. How do anti-SARS-CoV-2 mRNA vaccines protect from severe disease? Int J Mol Sci. 2022;23(18):10374. doi:10.3390/ijms231810374
   PubMed Web of Science ®Google Scholar
• Oyaert M, De Scheerder MA, Van Herrewege S, et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front Immunol. 2022;13:858399. doi:10.3389/fimmu.2022.858399
   PubMed Web of Science ®Google Scholar
• Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. doi:10.1136/bmj-2021-068632
   PubMedGoogle Scholar
• Okamoto A, Fujigaki H, Iriyama C, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022;6(11):3230–3233. doi:10.1182/bloodadvances.2021006302
   PubMed Web of Science ®Google Scholar
• Gurion R, Rozovski U, Itchaki G, et al. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2022;107(3):715–720. doi:10.3324/haematol.2021.279216
   PubMed Web of Science ®Google Scholar
• Shree T, Shankar V, Lohmeyer JJK, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022;3(2):95–102. doi:10.1158/2643-3230.BCD-21-0222
   PubMedGoogle Scholar
• Narita K, Nakaji S, Tabata R, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115(5):728–736. doi:10.1007/s12185-022-03305-z
   PubMed Web of Science ®Google Scholar
• Pascale SP, Nuccorini R, Pierri T, et al. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients. Front Immunol. 2022;13:892331. doi:10.3389/fimmu.2022.892331
   PubMed Web of Science ®Google Scholar
• Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053–3061. doi:10.1182/bloodadvances.2021005094
   PubMed Web of Science ®Google Scholar
• St-Pierre F, Doukas P, Boyer J, Nieves M. CLL-211 humoral immune response following COVID-19 vaccination in patients with Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): results from a large, single-center observational study. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S273. doi:10.1016/S2152-2650(22)01335-0
   Google Scholar
• Ollila TA, Masel RH, Reagan JL, et al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022;128(18):3319–3329. doi:10.1002/cncr.34354
   PubMed Web of Science ®Google Scholar
• Tanguay M, Boutin M, Laumaea A, et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022;40(9):1203–1207. doi:10.1016/j.vaccine.2022.01.040
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Sugiyama A, Tanaka T, et al. The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Health Sci Rep. 2022;5(3):e572. doi:10.1002/hsr2.572
   PubMedGoogle Scholar
• Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63. doi:10.1038/s41467-020-20247-4
   PubMed Web of Science ®Google Scholar
• Jeewandara C, Jayathilaka D, Gomes L, et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep. 2021;11(1):2062. doi:10.1038/s41598-021-81629-2
   PubMedGoogle Scholar
• Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318–327. doi:10.1038/s41423-020-00588-2
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Global Change Data Lab. Oxford martin school. Coronavirus (COVID-19) vaccinations-our world in data. Available from: https://ourworldindata.org/covid-vaccinations. Accessed January 19, 2023.
   Google Scholar
• Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26)::6769–6771. doi:10.1182/blood-2011-08-372649
   PubMed Web of Science ®Google Scholar
• Makatsori M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107(10):821–828. doi:10.1093/qjmed/hcu094
   PubMed Web of Science ®Google Scholar
• Mittelman M, Magen O, Barda N, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139(10):1439–1451. doi:10.1182/blood.2021013768
   PubMed Web of Science ®Google Scholar
• Naito T, Tsuchida N, Kusunoki S, et al. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study. Expert Rev Vaccines. 2022;21(9):1319–1329. doi:10.1080/14760584.2022.2093722
   PubMed Web of Science ®Google Scholar
• Focosi D, Casadevall A, Critical A. Analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment. Viruses. 2022;14(9):1999. doi:10.3390/v14091999
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, Wit SD, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188–2200. doi:10.1056/NEJMoa2116620
   PubMed Web of Science ®Google Scholar
• Lim SH, Stuart B, Joseph-Pietras D, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552–564. doi:10.1038/s43018-022-00364-3
   PubMedGoogle Scholar
• Nguyen Y, Flahault A, Chavarot N, et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022;22:00383.
   Google Scholar